Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.

S. Vrtala, K. Hirtenlehner, M. Susani, M. Akdis, F. Kussebi, C. A. Akdis, K. Blaser, P. Hufnagl, B. R. Binder, A. Politou, A. Pastore, L. Vangelista, W. R. Sperr, H. Semper, P. Valent, C. Ebner, D. Kraft, R. Valenta

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.

Original languageEnglish
Pages (from-to)2045-2047
Number of pages3
JournalFASEB Journal
Volume15
Issue number11
Publication statusPublished - Sep 2001
Externally publishedYes

Fingerprint

Allergies
Genetic engineering
Betula
Genetic Engineering
Pollen
allergens
genetic engineering
hypersensitivity
Allergens
Hypersensitivity
pollen
hay fever
T-Lymphocyte Epitopes
Seasonal Allergic Rhinitis
immunotherapy
prototypes
Immunotherapy
Immunoglobulin E
epitopes
B-lymphocytes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Vrtala, S., Hirtenlehner, K., Susani, M., Akdis, M., Kussebi, F., Akdis, C. A., ... Valenta, R. (2001). Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB Journal, 15(11), 2045-2047.

Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. / Vrtala, S.; Hirtenlehner, K.; Susani, M.; Akdis, M.; Kussebi, F.; Akdis, C. A.; Blaser, K.; Hufnagl, P.; Binder, B. R.; Politou, A.; Pastore, A.; Vangelista, L.; Sperr, W. R.; Semper, H.; Valent, P.; Ebner, C.; Kraft, D.; Valenta, R.

In: FASEB Journal, Vol. 15, No. 11, 09.2001, p. 2045-2047.

Research output: Contribution to journalArticle

Vrtala, S, Hirtenlehner, K, Susani, M, Akdis, M, Kussebi, F, Akdis, CA, Blaser, K, Hufnagl, P, Binder, BR, Politou, A, Pastore, A, Vangelista, L, Sperr, WR, Semper, H, Valent, P, Ebner, C, Kraft, D & Valenta, R 2001, 'Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.', FASEB Journal, vol. 15, no. 11, pp. 2045-2047.
Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB Journal. 2001 Sep;15(11):2045-2047.
Vrtala, S. ; Hirtenlehner, K. ; Susani, M. ; Akdis, M. ; Kussebi, F. ; Akdis, C. A. ; Blaser, K. ; Hufnagl, P. ; Binder, B. R. ; Politou, A. ; Pastore, A. ; Vangelista, L. ; Sperr, W. R. ; Semper, H. ; Valent, P. ; Ebner, C. ; Kraft, D. ; Valenta, R. / Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. In: FASEB Journal. 2001 ; Vol. 15, No. 11. pp. 2045-2047.
@article{0182bf6809ae4387a60ba6871dcf7ae4,
title = "Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.",
abstract = "An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.",
author = "S. Vrtala and K. Hirtenlehner and M. Susani and M. Akdis and F. Kussebi and Akdis, {C. A.} and K. Blaser and P. Hufnagl and Binder, {B. R.} and A. Politou and A. Pastore and L. Vangelista and Sperr, {W. R.} and H. Semper and P. Valent and C. Ebner and D. Kraft and R. Valenta",
year = "2001",
month = "9",
language = "English",
volume = "15",
pages = "2045--2047",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "11",

}

TY - JOUR

T1 - Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.

AU - Vrtala, S.

AU - Hirtenlehner, K.

AU - Susani, M.

AU - Akdis, M.

AU - Kussebi, F.

AU - Akdis, C. A.

AU - Blaser, K.

AU - Hufnagl, P.

AU - Binder, B. R.

AU - Politou, A.

AU - Pastore, A.

AU - Vangelista, L.

AU - Sperr, W. R.

AU - Semper, H.

AU - Valent, P.

AU - Ebner, C.

AU - Kraft, D.

AU - Valenta, R.

PY - 2001/9

Y1 - 2001/9

N2 - An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.

AB - An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.

UR - http://www.scopus.com/inward/record.url?scp=0035462111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035462111&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 2045

EP - 2047

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 11

ER -